Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + iodine-131
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Oral
01
Overview
Anlotinib + iodine-131 is an investigational combination regimen consisting of the oral multi-kinase tyrosine kinase inhibitor anlotinib and the therapeutic radiopharmaceutical iodine-131 (radioiodine). Anlotinib targets tumor angiogenesis and proliferation pathways by inhibiting VEGFR, FGFR, PDGFR, and c-Kit, and has been shown to potentially enhance or restore radioactive iodine uptake in thyroid cancer cells. Iodine-131 delivers targeted cytotoxic beta and gamma radiation to iodine-avid thyroid tumor cells. This combination is being evaluated in clinical trials, including a single-arm Phase II study, for the treatment of distant metastatic differentiated thyroid cancer (dmDTC).
- Other names
- anlotinib + 131Ianlotinib + radioiodineanlotinib hydrochloride + iodine-131anlotinib hydrochloride + radioiodine (131I)
02
Targets
DNAEGFR (Epidermal growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)NIS (Human sodium iodide symporter)
Beyond the preview
Go deeper on anlotinib + iodine-131.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + iodine-131.
Work on anlotinib + iodine-131? Claim this page to correct or add information. Claim this page